Respiratory syncytial virus (RSV) is commonly known as a pathogen of the bronchiolitis in children, however, recently also as a pathogen of the severe virus pneumonia in adults, especially elderly persons, and vaccines for elderly persons have been developed. There are two vaccines, such as the vaccines targeted for subgroup A with the adjuvant, and that targeted for both subgroup A and B but not included the adjuvant in Japan. Both vaccines are considered effective to prevent not only the incident of RSV infection/pneumonia, but also the exacerbations of the elderly persons with underlying diseases including chronic cardiopulmonary diseases.

Background: In December 2019, a cluster of patients with unexplained viral pneumonia was identified in Wuhan, China. Since March 11^th 2020 the WHO declared COVID 19 as a pandemic with rising number of cases all over the world. Aim of the work: The aim of the study was to measure the percentages of possible, probable and provisionally excluded cases among the first 500 attendants of the triage of Ain Shams University Hospital and describe their epidemiological and clinical characteristics. Patients and Methods: This was a retrospective descriptive case series study including the first 500 patients attending the triage of Ain Shams University Hospitals from March 29th to May 31st. A constructed questionnaire in the form of a scoring system was used and data was collected through interviewing the patients after appropriate consent. Results: As regard the scoring system, 72.2% of patients had new onset of cough or old worsened cough in the previous 3 days, 59.2% had sore throat and 59% had dyspnea. Out of the 500 cases 33.2% were probable, 38.2% were possible and 28.2% were provisionally excluded. Conclusion: COVID-19 pneumonia usually occurred at an age younger than 47 years and it was more predominant in the male gender. The most common initial clinical presentations were new dry cough or chronic cough with worsening over the last 3 days, sore throat and/or runny nose and fever. Thirty-eight percent were classified as possible COVID-19 cases, and 33% were classified as probable.

Introduction: The city of Wuhan in China reported the first case of coronavirus, termed as SARS-CoV-2, in December 2019. To date, 187,827,660 cases have been reported to the WHO (3). With current research focusing on potential therapeutic agents for the coronavirus disease and vaccines, there remain major gaps in our understanding of the pathophysiology and clinical course of this viral pneumonia. Secondary infections are one of them. In this systematic review, we analyze the outcomes of two fungal infections in patients of COVID-19, viz. Mucormycosis and candida. Methodology: A systematic review has been done on secondary infections with mucor and candida fungi in patients of COVID-19. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were used. Twenty-three studies were included in the final analysis. Our review included studies from various countries across the globe. The risk of bias was analyzed using the NIH Quality Assessment Tool for Case Series Studies. This study did not require ethical approval as data was obtained from already available databases, and patients were not directly involved. Results: A total of 23 articles were included in the final review and the total number of patients included was 79 Male: female ratio was calculated to be 1.6 and the average age of patients was 52 years (ranging from 24-86 years). Various types of comorbidities were seen in the included patients, the most common being diabetes mellitus. Among the 18 patients in the cohort of mucormycosis, 7 patients died and four studies did not report patient outcomes. Among the 61 patients, 13 patients died and one patient was still ventilated at the time of publication. Conclusion: Secondary infections after COVID-19 are a cause of major concerns. Further studies and case reports are needed to better understand the various other types of secondary infections and also to formulate strategies to prevent these.